Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were down 16.7% during mid-day trading on Tuesday . The company traded as low as C$0.10 and last traded at C$0.10. Approximately 236,500 shares traded hands during mid-day trading, a decline of 15% from the average daily volume of 279,794 shares. The stock had previously closed at C$0.12.
Hemostemix Stock Performance
The business has a fifty day simple moving average of C$0.09 and a 200 day simple moving average of C$0.07. The stock has a market cap of C$9.15 million, a price-to-earnings ratio of -5.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What Is WallStreetBets and What Stocks Are They Targeting?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Energy and Oil Stocks Explained
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
